OTCPK:HYBT

Stock Analysis Report

Heyu Biological Technology

Executive Summary

Heyu Biological Technology Corporation does not have significant operations.


Snowflake Analysis

Imperfect balance sheet with weak fundamentals.

Share Price & News

How has Heyu Biological Technology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HYBT has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

0%

HYBT

-6.6%

US Software

-4.2%

US Market


1 Year Return

-82.0%

HYBT

29.5%

US Software

14.0%

US Market

Return vs Industry: HYBT underperformed the US Software industry which returned 35.1% over the past year.

Return vs Market: HYBT underperformed the US Market which returned 17.8% over the past year.


Shareholder returns

HYBTIndustryMarket
7 Day0%-6.6%-4.2%
30 Day0%1.8%-1.8%
90 Day-80.0%8.4%2.6%
1 Year-82.0%-82.0%30.8%29.5%16.3%14.0%
3 Year-83.5%-83.5%138.3%128.2%43.2%34.0%
5 Year-97.2%-97.2%203.2%181.5%65.9%47.6%

Price Volatility Vs. Market

How volatile is Heyu Biological Technology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Heyu Biological Technology undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Heyu Biological Technology is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Heyu Biological Technology has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of HYBT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Heyu Biological Technology regulatory filings here.
  • Explore potentially undervalued companies in the Software industry.

Future Growth

How is Heyu Biological Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.1%

Forecasted Software industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Heyu Biological Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of HYBT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Heyu Biological Technology's filings and announcements here.
  • Explore growth companies in the Software industry.

Past Performance

How has Heyu Biological Technology performed over the past 5 years?

39.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HYBT is currently unprofitable.

Growing Profit Margin: HYBT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HYBT is unprofitable, but has reduced losses over the past 5 years at a rate of 39.8% per year.

Accelerating Growth: Unable to compare HYBT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HYBT is unprofitable, making it difficult to compare its past year earnings growth to the Software industry (18.4%).


Return on Equity

High ROE: HYBT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Heyu Biological Technology's financial position?


Financial Position Analysis

Short Term Liabilities: HYBT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: HYBT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: HYBT has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: HYBT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: HYBT has a high level of physical assets or inventory.

Debt Coverage by Assets: HYBT has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HYBT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: HYBT has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 27.6% each year.


Next Steps

Dividend

What is Heyu Biological Technology's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate HYBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HYBT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HYBT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HYBT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HYBT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Ban Ang (44yo)

1.8yrs

Tenure

0

Mr. Ban Siong Ang is Chairman of the Board, Chief Executive Officer and President at Heyu Biological Technology Corporation and also serves as its Group Managing Director. Mr. Ang serves as the Chief Execu ...


Leadership Team

NamePositionTenureCompensationOwnership
Ban Ang
Chairman of the Board1.8yrsno data88.34% $3.3m
Wei Li
CFO, Secretary & Treasurer1.8yrsno datano data
Hung Tan
Executive Director1.8yrsno data4.84% $180.0k

1.8yrs

Average Tenure

44yo

Average Age

Experienced Management: HYBT's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Ban Ang
Chairman of the Board1.8yrsno data88.34% $3.3m
Hung Tan
Executive Director1.8yrsno data4.84% $180.0k
Stephan Busch
Director0.6yrsno datano data
Kwee Huwa Tan
Director1.3yrsno data0.77% $28.8k
Senad Busatlic
Independent Director0.6yrsno datano data

1.3yrs

Average Tenure

54yo

Average Age

Experienced Board: HYBT's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 207.9%.


Top Shareholders

Company Information

Heyu Biological Technology Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Heyu Biological Technology Corporation
  • Ticker: HYBT
  • Exchange: OTCPK
  • Founded: 1987
  • Industry: Application Software
  • Sector: Software
  • Market Cap: US$3.717m
  • Shares outstanding: 1.03b
  • Website: https://heyubt.com

Number of Employees


Location

  • Heyu Biological Technology Corporation
  • No. 10 Building
  • 4th Floor
  • Xiamen
  • Fujian Province
  • 361022
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HYBTOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 1999

Biography

Heyu Biological Technology Corporation does not have significant operations. Previously, the company was engaged in the provision of application services; and development of business software technologies and services for business merchants and organizations. The company was formerly known as Pacific WebWorks, Inc. and changed its name to Heyu Biological Technology Corporation in June 2018. Heyu Biological Technology Corporation was incorporated in 1987 and is based in Xiamen, the People's Republic of China. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 00:34
End of Day Share Price2020/02/19 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.